Evidence map›Paper›PMID 40059143›Full record

ArticleJournal of nanobiotechnology2025

Platelet hitchhiking vascular-disrupting agents for self-amplified tumor-targeting therapy.

Hongyu Chu, Yajun Xu, Yuezhan Shan, Mengmeng Sun, Weidong Zhao, Xuedong Fang, Na Shen, Zhaohui Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Vascular Disruption Therapy as a New Strategy for Cancer Treatment.International journal of molecular sciences · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongyu ChuDepartment of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Yajun XuKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
Yuezhan ShanDepartment of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Mengmeng SunDepartment of Thyroid, The Second Hospital of Jilin University, Changchun, 130041, China.
Weidong ZhaoKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
Xuedong FangDepartment of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. fangxd@jlu.edu.cn.
Na ShenKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China. nshen@ciac.ac.cn.
Zhaohui TangKey Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China. ztang@ciac.ac.cn.

Funding

Ministry of Science and Technology of China 2022YFE0110200National Natural Science Foundation of China 52273157, 52073279, 52025035National Natural Science Foundation of Jilin Province 20230508102RC, 20240305041YYYouth Innovation Promotion Association of the Chinese Academy of Sciences 2022224
6 · The paper itself

Abstract

The vascular-disrupting agent DMXAA (5,6-dimethylxanthone-4-acetic acid) exhibits potent anticancer activity by targeting tumor vasculature and activating immune responses via the cGAS-STING pathway. However, its clinical application is hindered by nonspecific targeting and significant cardiovascular toxicity. This study introduces a novel self-amplified tumor-targeting delivery system(P@NPPD)comprising azide-functionalized poly(ethylene glycol)-b-poly-[(N-2-hydroxyethyl)-aspartamide]-DMXAA (N

Indexed as

Antineoplastic AgentsBlood PlateletsDrug Delivery SystemsNeoplasmsXanthonesAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CPolyethylene GlycolsAntineoplastic AgentsPolyethylene GlycolsvadimezanXanthonesDMXAAImmune activationPlatelet-conjugated nanocarrierSelf-amplified targetingVascular disrupting agent

Identifiers

PMID40059143
PMCPMC11892306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.